-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Author Index: A

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Abdel-Wahab, O.
107 - Single-Cell Multi-Omics in Human Clonal Hematopoiesis Reveals That DNMT3A R882 Mutations Perturb Early Progenitor States through Selective Hypomethylation
273 - Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
388 - Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG
518 - ZRSR2 Mutation Induced Minor Intron Retention Drives MDS and Diverse Cancer Predisposition Via Aberrant Splicing of LZTR1
521 - Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis
542 - LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study
1307 - MRD-Driven Time Limited Therapy with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Previously Untreated Chronic Lymphocytic Leukemia
1311 - Phase 1 and Dose Expansion Study of APR-246 in Combination with Ibrutinib or Venetoclax-Based Therapy in Subjects with TP53-Mutant Relapsed and/or Refractory Non-Hodgkin Lymphomas (NHL) Including Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
2843 - Venetoclax Therapy for Relapsed and Treatment Refractory AML: Clinical Outcomes and Molecular Predictors
SCI-33 - Understanding and Targeting Spliceosomal Gene Mutations in Leukemia
Abruzzese, E.
50 - Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study
647 - Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic
648 - Peripheral Blood CD26+ Leukemia Stem Cells Monitoring in Chronic Myeloid Leukemia Patients from Diagnosis to Response to TKIs: Interim Results of a Multicenter Prospective Study (PROSPECTIVE FLOWERS)
1164 - Antiemetic Prophylaxis with NEPA (NETUPITANT/PALONOSETRON) and Dexamethasone to Prevent Chemotherapy-Induced Nausea and Vomiting (CINV) in Hodgkin’S Lymphoma Naïve Patients Receiving ABVD Regimen: A Multicenter Phase Iia Study
1238 - Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study
1584 - Impact on Mental Health, Disease Management and Socioeconomic Modifications in Hematological Patients during COVID-19 Pandemia in Italy
2124 - IgM-Secreting Diffuse Large B-Cell Lymphoma (DLBCL) Is a Poor Prognostic Subset within the Non-Germinal-Centre-Type (GC-type): An Italian Multicentre Study
2146 - Multidimensional Vascular Evaluation in Patients Treated with Tyrosine Kinase Inhibitors (TKIs): From Plaque Formation to Evolution and Follow up on 150 Patients
2156 - Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib
Ahmed, S.
189 - A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine ± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS
645 - A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL)
1129 - Complex Karyotype Is a Significant Predictor for Worst Outcomes in Patients with Mantle Cell Lymphoma (MCL) Treated with BTK Inhibitors – Comprehensive Analysis of 396 Patients
1138 - Comprehensive Analysis of Factors Predictive for Time to Transformation and Risk of Transformation in Patients (pts) with Mantle Cell Lymphoma
1172 - Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center
1511 - Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience
2042 - Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) – a Phase II Clinical Trial
2058 - Outcomes of Acalabrutinib Failures in Relapsed Mantle Cell Lymphoma
2119 - Prognostic Value of Delta Lymphocyte Index (DLIx) in Patients with Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy
2128 - Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma
2983 - Association of Epstein–Barr Virus with Advanced Stage and Survival Outcomes in Classic Hodgkin’s Lymphoma
3063 - The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL)
Ailawadhi, S.
179 - Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma
181 - A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)
1333 - Treatment Patterns and Outcomes of Multiple Myeloma (MM) with Chromosome Translocation (11;14) in United States (US) Routine Clinical Practice
1407 - A Phase I Dose Escalation Study of PT-112 in Patients with Relapsed or Refractory Multiple Myeloma
2328 - Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL)
3198 - Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience
3242 - Real-World Treatment Patterns and Outcomes of Proteasome Inhibitor (PI: Bortezomib [V], Carfilzomib [K], or Ixazomib [I])-Lenalidomide/Dexamethasone (Rd)-Triplets By Prior Lenalidomide-Exposure in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Engaged in Routine Care in the United States (US)
3244 - Clinical Features and Survival Outcomes in Diabetic Patients with Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect® MM Registry
- Racial Disparities in Outcomes of Lymphoid Malignancies: Paving a Path Forward
- Live Q&A and Panel Discussion
Al Malki, M. M.
76 - Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens
192 - Total Marrow and Lymphoid Irradiation (TMLI) at a Dose of 2000cGy in Combination with Post-Transplant Cyclophosphamide (PTCy)-Based Graft Versus Host Disease (GvHD) Prophylaxis Is Safe and Associated with Favorable GvHD-Free/Relapse-Free Survival at 1 Year in Patients with Acute Myeloid Leukemia (AML)
298 - Efficacy of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial
330 - The First-in-Class Anti-CD47 Antibody Magrolimab Combined with Azacitidine Is Well-Tolerated and Effective in AML Patients: Phase 1b Results
739 - Preliminary Results of the First-in-Human Study of Nexi-001, a Multi-Antigen Specific CD8+ T Cell Product, in Acute Myeloid Leukemia (AML) Patients with Relapsed Disease after Allogeneic Hematopoietic Cell Transplantation (Allo-HSCT) Demonstrate Early Signs of Safety, Tolerability and Robust Immune Responses
991 - Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351)
1464 - Healthcare Resource Utilization in Transplant Patients Who Are at a Higher-Risk to Develop Cytomegalovirus Infection during Their Primary Transplant-Related Hospitalization
1470 - Hemorrhagic Cystitis in Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Post Transplant Cyclophosphamide As GvHD Prophylaxis
1518 - Improving Donor Selection for Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide through Selective HLA-Mis/Matching
3351 - Alternative Donor Hematopoietic Cell Transplantation for Pediatric, Adolescent and Young Adult with Hematological Diseases
3357 - Clinical Impact of Cytokine Release Syndrome on Outcomes of Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide
Al-Mondhiry, J.
Alatrash, G.
169 - Overexpression of CD200 Is a Stem Cell-Specific Mechanism of Immune Escape in AML
690 - Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy
1458 - Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Outcomes of Prospective Phase II Clinical Trial
1909 - Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML)
2348 - Lower Risk of Graft Versus Host Disease after Exposure to Checkpoint Inhibitors with the Use of Post-Transplant Cyclophosphamide Prophylaxis
2368 - Transplant Outcomes with Fludarabine and Melphalan in High Risk AML Patients By Donor Types
2809 - Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy
3101 - Immunologic Predictors for Clinical Responses in Patients with Myelodysplastic Syndromes Treated with Immune Checkpoint Blockade
3328 - Maintenance Treatment with Guadecitabine (SGI-110) in High Risk MDS and AML Patients after Allogeneic Stem Cell Transplantation
3359 - Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax- Based Therapy
Aldoss, I.
192 - Total Marrow and Lymphoid Irradiation (TMLI) at a Dose of 2000cGy in Combination with Post-Transplant Cyclophosphamide (PTCy)-Based Graft Versus Host Disease (GvHD) Prophylaxis Is Safe and Associated with Favorable GvHD-Free/Relapse-Free Survival at 1 Year in Patients with Acute Myeloid Leukemia (AML)
298 - Efficacy of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial
331 - Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia
991 - Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351)
994 - Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML)
1470 - Hemorrhagic Cystitis in Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Post Transplant Cyclophosphamide As GvHD Prophylaxis
1482 - Vaccination of Hematopoietic Stem Cell (HCT) Donors with Triplex, a Novel Cytomegalovirus Vaccine: Safety, Feasibility and Adoptive Transfer of Protective CMV-Specific T Cells in HCT Recipients
2001 - TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia
2817 - Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab
2878 - Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia
Ali, H.
192 - Total Marrow and Lymphoid Irradiation (TMLI) at a Dose of 2000cGy in Combination with Post-Transplant Cyclophosphamide (PTCy)-Based Graft Versus Host Disease (GvHD) Prophylaxis Is Safe and Associated with Favorable GvHD-Free/Relapse-Free Survival at 1 Year in Patients with Acute Myeloid Leukemia (AML)
298 - Efficacy of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial
991 - Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351)
1470 - Hemorrhagic Cystitis in Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Post Transplant Cyclophosphamide As GvHD Prophylaxis
1488 - Safety Analysis of Patients Who Received Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease in an Expanded Access Program
2986 - A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis
3000 - A Phase 1/2 Study of INCB000928 As Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)
3351 - Alternative Donor Hematopoietic Cell Transplantation for Pediatric, Adolescent and Young Adult with Hematological Diseases
3357 - Clinical Impact of Cytokine Release Syndrome on Outcomes of Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide
Almeida de Jesus, A.
Alousi, A. M.
28 - Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML)
189 - A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine ± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS
1458 - Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Outcomes of Prospective Phase II Clinical Trial
1506 - African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis
1511 - Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience
2348 - Lower Risk of Graft Versus Host Disease after Exposure to Checkpoint Inhibitors with the Use of Post-Transplant Cyclophosphamide Prophylaxis
2368 - Transplant Outcomes with Fludarabine and Melphalan in High Risk AML Patients By Donor Types
2390 - Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft Versus Host Disease
2409 - Minimal Residual Disease Eradication with Guadecitabine (SGI-110) in the Post-Transplant Setting
3328 - Maintenance Treatment with Guadecitabine (SGI-110) in High Risk MDS and AML Patients after Allogeneic Stem Cell Transplantation
3331 - High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) with Consolidative Radiation Therapy (RT) for Relapsed or Refractory (R/R) Primary Mediastinal B-Cell Lymphoma (PMBCL): 20-Year Experience at MD Anderson Cancer Center (MDACC)
3359 - Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax- Based Therapy
Altman, J. K.
Alvarado, Y.
26 - Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3-ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial
28 - Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML)
464 - Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study
590 - Response Patterns and MRD By Flow Cytometry and NGS in Patients with Mutant-IDH Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents
637 - Ten-Day Decitabine with Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score Matched Analysis
652 - Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib
693 - Outcomes of TP53-Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine
987 - Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
1014 - Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study
1061 - Outcomes of De Novo Acute Myeloid Leukemia with Monocytic Differentiation (FAB M4/5) Treated with Venetoclax and Decitabine
1288 - Updated Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Previously-Untreated Patients with Higher-Risk Myelodysplastic Syndrome
1289 - Initial Results of a Phase I/II Study of Venetoclax in Combination with Azacitidine in Treatment-Naive and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
1908 - The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408)
1932 - Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse
2150 - The Comparison of Frontline Lower-Dose Dasatinib 50 Mg/Day to Standard-Dose Dasatinib 100 Mg/Day in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis
2159 - Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study
2196 - Long-Term Outcome of Low-Dose Hypomethylating Agents in Lower-Risk Myelodysplastic Syndromes: A Randomized Phase 2 Study
2203 - A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)
2833 - Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial
2837 - Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis
2854 - Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
3119 - Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS)
3120 - Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy
3138 - Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results
Anampa- Guzmán, A.
Anderson, K.
61 - High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma
143 - Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial
215 - Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub
487 - Disruption of the m-SWI/SNF Complex Mediated By Recurrent Non-Coding Mutations in BCL7A Induces Tumor Cell Proliferation in Multiple Myeloma
665 - Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application
667 - Restoring NK Cell Activities in Multiple Myeloma with IL-15 Receptor Agonist NKTR-255
721 - Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma
950 - Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition
1323 - Analysis of Sars-Cov-2-Associated Proteins Identify Tank-Binding Kinase-1 As an Immunotherapeutic Target in Multiple Myeloma
1398 - A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts
2233 - Proteomic Characterization of Ubiquitin Receptor ADRM1/Rpn13
2238 - Blockade of Deubiquitylating Enzyme USP7 in Plasmacytoid Dendritic Cells Stimulates Anti-Myeloma Immunity
2270 - RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma
2272 - Activation of the ERK Pathway Drives Acquired Resistance to Venetoclax in MM Cell Models
2273 - Pre-Clinical Validation of a Novel Erk1/2 and CDK4/6 Inhibitor Combination in Multiple Myeloma (MM)
2283 - A High Throughput Quantitative Seroproteomics Analysis of Multiple Myeloma Patients on Tagraxofusp Therapy Identifies Novel Cytokine-Assisted Mechanism of Action
3155 - Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature
3188 - A Novel CD138-Targeting Monoclonal Antibody Induces Potent Myeloma Killing and Further Synergizes with IMiDs or Bortezomib in in Vitro and In Vivo Preclinical Models of Human Multiple Myeloma
3189 - TRAF2 Mediates Sensitivity to Immunomodulatory Drugs in the Bone Marrow Microenvironment
3192 - Enhancing the Immune Surveillance in Multiple Myeloma Via CDK4/6 Inhibition
Anderson, Jr., L. D.
133 - Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma
549 - Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
1367 - Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis
1385 - Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study
2297 - Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study
3215 - Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study
3245 - Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study
Andreeff, M.
25 - Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
26 - Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3-ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial
29 - Outcomes with Sequential FLT3-Inhibitor (FLT3i) Based Therapies in Patients (pts) with FLT3-Mutated Acute Myeloid Leukemia (AML) Exposed to Prior FLT3i Based Therapies
32 - High-Dimensional Single-Cell Proteomic Analysis Reveals Therapeutic Vulnerabilities in Relapsed/Refractory AML By Concomitant Analysis of Cell Surface Antigens, Signaling Pathways and Anti-Apoptotic Proteins
265 - Targeting E-Selectin with GMI-1271 Overcomes Microenvironment-Mediated Resistance to Venetoclax/HMA Therapy
276 - Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia
335 - Patterns of Secondary Resistance Differ in Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Type I Versus Type II FLT3-Inhibitors (FLT3i’s)
390 - Prognostic and Therapeutic Implications of Mutant TP53 Variant Allelic Frequency in Adults with Newly Diagnosed TP53­-Mutated Acute Myeloid Leukemia
527 - Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor
913 - Mdm2 Haplo-Insufficiency in Hematopoietic and Mesenchymal Progenitor Cells Results in Cell Death
954 - MDS1-EVI1 Complex (MECOM) Activation Promotes Leukemic Stem Cell Quiescence By Upregulating CDKN1C/P57Kip2
956 - Co-Targeting MCL-1 and BCL-2 Is Highly Synergistic in BH3 Mimetic- and Venetoclax/Hypomethylating Agent-Resistant and TP53 Mutated AML
958 - The Novel Dihydroorotate Dehydrogenase (DHODH) Inhibitor PTC299 Inhibit De Novo Pyrimidine Synthesis with Broad Anti-Leukemic Activity Against Acute Myeloid Leukemia
960 - The Direct Interactions with Bone Marrow Microenvironment Confer Resistance to the Inhibition of Oxidative Phosphorylation in AML
987 - Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
997 - Predictors of Early Mortality, Response, and Survival in Newly Diagnosed Acute Myeloid Leukemia (AML) Using a Contemporary Academic Cohort
1041 - Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response
1055 - High Efficacy of Liposomal Annamycin (L-ANN) in Combination with Cytarabine in Syngeneic p53-Null AML Mouse Model
1288 - Updated Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Previously-Untreated Patients with Higher-Risk Myelodysplastic Syndrome
1848 - Osterix Marks a Distinct Population of Circulatory Bone Marrow Mesenchymal Stem Cells That Is Increased upon Oncogenic Stress
1880 - Clonal Expansion of Mutant p53 Clones By MDM2 Inhibition in Acute Myeloid Leukemias
1915 - Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) across Therapy Groups
1961 - Venetoclax Enhances Anti-Leukemia Activity of CD123-Specific BiTE-Secreting T-Cells in AML
1963 - Dual CXCR4 and E-Selectin Inhibition (GMI-1359) Rapidly Increases AML Cellular Motility Prior to Intravasation and Vascular Niche Depletion Observed By Intravital Bone Marrow Two-Photon Microscopy
1978 - AML Cells Alter Bone Homeostasis By Promoting the Formation of Immature Bone and Resorption of Mature Bone That Supports Leukemia Progression
2159 - Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study
2201 - Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis
2218 - Ibrutinib Induces Durable Remissions in Treatment-Naïve CLL Patients with 17p Deletion/TP53 Mutations: Five Year Follow-up from a Phase 2 Study
2468 - High Dimensional Interrogation of Stress Response Patterns and Cell Death Modes in AML
2772 - Mdm2 Loss of Heterozygosity Cooperates with Mutant p53 in Acute Myeloid Leukemia
2775 - Exportin-1 (XPO1) Inhibition Sequesters p53 from MDM2 and MDM4 and Is Highly Synergistic with MDM2 Inhibition in Inducing Apoptosis in Wild-Type p53 Acute Myeloid Leukemias
2783 - Targeting Mcl-1 Enhances the Activity of Tyrosine Kinase Inhibitor Gilteritinib in FLT3 Mutated AML
2785 - BCL2A1: A Novel Target in Refractory Acute Myeloid Leukemia with FLT3-ITD/D835 Dual Mutations
2811 - Predictors of Outcomes in Adult AML with MLL Rearrangements
2822 - Clinical Course, Outcomes and Genetic Characterization of Patients with Isolated Myeloid Sarcoma
2854 - Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
2865 - Combined Blockage of E-Selectin and CXCR4 (GMI-1359) Enhances Anti-Leukemia Effect of FLT3 Inhibition (Sorafenib) and Protects Hematopoiesis in Pre-Clinical AML Models
2897 - Mapping the Architecture of Adverse Risk AML Using Single-Cell RNA Sequencing
3120 - Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy
3375 - Inhibition of EZH1 and EZH2 Restores Chemosensitivity of Leukemia Stem Cells in Acute Myeloid Leukemia By Recruitment of Quiescent AML Stem/Progenitor Cells
Ansell, S. M.
146 - Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL)
349 - Pre-Existing T Cell Subsets Determine Anti-PD1 Blockade Response in Richter’s Transformation
400 - Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy
474 - Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma
596 - High-Dimensional and Single-Cell Transcriptome Analysis of AITL Tumor Microenvironment Reveals Gross Expansion of Novel Dysfunctional CD8+ T Cell Populations, Global Shift in B Cell Phenotypes
646 - Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies
737 - Lines of Therapy before Autologous Stem Cell Transplant (ASCT) and CAR-T Infusion Affect Outcomes in Aggressive Non-Hodgkin’s Lymphoma (NHL)
1117 - High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles
1141 - Waldenström Macroglobulinemia in the Very Elderly (≥75 years):Clinical Characteristics and Outcomes
1192 - Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E
1222 - Response to Bridging Therapy (BT) before CAR-T Cell Infusion Predicts Outcomes for Relapsed/Refractory (R/R) Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)
1505 - Infused Autograft-Absolute Lymphocyte Count Predicts Superior Survival in Diffuse Large B-Cell Lymphoma Patients Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation: A Matched-Control Study
2022 - Global Transcriptional States of Follicular Lymphoma B Cells Highlight Distinct Groups of Tumor Identity Associated with Somatic Alterations and Tumor Microenvironment
2041 - R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET
2046 - Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study
2056 - Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis
2206 - Identification of a Novel Role for PD-1 Signaling in Promotion Tumor Proliferation in B-Cell Lymphoma
2973 - Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study
3150 - Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience
3473 - The Utility of Granulocyte Colony Stimulating Factor in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy with Axicabtagene Ciloleucel
- Fundamentals of Immunology for Understanding Immunotherapy
Anwer, F.
438 - Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the PRISM score
729 - Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis
1029 - Azacitidine Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Systematic Review
1473 - Reduced-Intensity Versus Myeloablative Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials & Cohort Studies
1484 - Anti-Thymocyte Globulin (ATG) for Prophylaxis of Severe Graft Vs. Host Disease after Hematopoietic Stem Cell Transplant: A Systematic Review and Meta-Analysis
1500 - Safety and Efficacy of Salvage Therapies for Relapse/Refractory AML/MDS after First Allogeneic Hematopoietic Stem Cell Transplant: A Systematic Review
1504 - Post-Transplant Lymphoproliferative Disorder after Solid Organ Transplant in the Pediatric Population: A Systematic Review
1739 - Clinical Outcomes of Malignancy-Related Neutropenic Fever Admissions in the United States: A 10-Year National Study
1755 - Acute Coronary Syndrome in Patients with Thrombotic Thrombocytopenic Purpura
2313 - Maintenance Therapy in Newly Diagnosed and Transplant Ineligible Multiple Myeloma Patients: A Meta-Analysis
2373 - Efficacy and Safety of Recombinant Thrombombomodulin for the Prophylaxis of Vaso-Occlusive Complications in Allogenic Hematopoietic Stem Cell Transplantation : A Systematic Review and Meta-Analysis
2382 - Efficacy and Safety Profile of Proteasome Inhibitor Based Drug Regimens for Treatment of Newly Diagnosed AL Amyloidosis: A Systematic Review
2593 - Efficacy and Safety of Amlodipine in Preventing Myocardial Iron Overload in Patients with Transfusion-Dependent Thalassemia Major : A Systematic Review and Meta-Analysis
3281 - Hematopoietic Progenitor Cell Mobilization and Collection for Autologous Hematopoietic Cell Transplantation in AL Amyloidosis: A Single Center Experience
Assouline, S. E.
125 - Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)
701 - A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results
702 - Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial
1105 - The Copy Number Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma
1953 - CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study
1998 - Single-Cell Transcriptomic Profiling of De Novo and Relapsed Acute Myeloid Leukemia Identifies a Leukemic Stemness Program Shared across Diverse Phenotypes
2047 - Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response
2096 - Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts
3003 - Secondary Erythrocytosis Is Phenotypically Distinct from Polycythemia Vera but Associated with Comparable Rates of Thrombosis at Diagnosis
3020 - Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension
3066 - Retro-Prospective Observational Study on the Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO)
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z